MX2015014773A - Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja. - Google Patents

Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja.

Info

Publication number
MX2015014773A
MX2015014773A MX2015014773A MX2015014773A MX2015014773A MX 2015014773 A MX2015014773 A MX 2015014773A MX 2015014773 A MX2015014773 A MX 2015014773A MX 2015014773 A MX2015014773 A MX 2015014773A MX 2015014773 A MX2015014773 A MX 2015014773A
Authority
MX
Mexico
Prior art keywords
egfr antibodies
cancer treatments
low fucosylation
cancer
antibodies
Prior art date
Application number
MX2015014773A
Other languages
English (en)
Spanish (es)
Inventor
Steffen Goletz
Antje Danielczyk
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of MX2015014773A publication Critical patent/MX2015014773A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2015014773A 2013-04-22 2014-04-22 Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja. MX2015014773A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13002106 2013-04-22
EP13002108 2013-04-22
PCT/EP2014/058118 WO2014173886A1 (en) 2013-04-22 2014-04-22 Anti-cancer treatments with anti-egfr antibodies having a low fucosylation

Publications (1)

Publication Number Publication Date
MX2015014773A true MX2015014773A (es) 2016-03-04

Family

ID=50729450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014773A MX2015014773A (es) 2013-04-22 2014-04-22 Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja.

Country Status (13)

Country Link
US (1) US20160068609A1 (enExample)
EP (1) EP2989126A1 (enExample)
JP (1) JP2016516800A (enExample)
KR (1) KR20150144804A (enExample)
CN (1) CN105229030A (enExample)
AU (1) AU2014257650A1 (enExample)
BR (1) BR112015025955A2 (enExample)
CA (1) CA2908819A1 (enExample)
EA (1) EA201591977A1 (enExample)
MX (1) MX2015014773A (enExample)
SG (1) SG11201507743XA (enExample)
WO (1) WO2014173886A1 (enExample)
ZA (1) ZA201507246B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
CN105820248A (zh) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型抗egfr单克隆抗体的制备方法及应用
CN105399830B (zh) * 2015-09-08 2019-11-19 北京天广实生物技术股份有限公司 抗egfr人源化单克隆抗体、其制备方法及用途
EP3400248A4 (en) * 2016-01-10 2019-09-04 Sorrento Therapeutics, Inc. IMPROVED SAFETY FOR THE TREATMENT OF CANCER WITH GLYCOSYLATED CHIMERIC ANTIBODY AGAINST EGFR
HUE058745T2 (hu) * 2016-04-27 2022-09-28 Green Cross Corp Hatóanyagként epidermális növekedési faktor receptorhoz specifikusan kötõdõ antitestet tartalmazó gyógyászati készítmény rák áttételének gátlására
CN116333130A (zh) 2016-05-24 2023-06-27 英斯梅德股份有限公司 抗体及其制备方法
WO2018013673A1 (en) 2016-07-13 2018-01-18 Reform Biologics, Llc Stabilizing excipients for therapeutic protein formulations
KR101884614B1 (ko) 2016-10-11 2018-08-02 신일제약주식회사 Fab 단편 및 이의 용도
US20200148785A1 (en) * 2017-03-29 2020-05-14 Glycotope (GmbH) Pd-l1 and ta-muc1 antibodies
JP7160833B2 (ja) * 2017-04-13 2022-10-25 サイロパ ビー.ブイ. 抗sirpアルファ抗体
CA3064333A1 (en) * 2017-05-29 2018-12-06 Gamamabs Pharma Cancer-associated immunosuppression inhibitor
WO2019222282A1 (en) * 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113164480B (zh) * 2018-11-14 2023-11-28 学校法人金泽医科大学 用于治疗弥漫性胃癌的药物组合物
CN112300278A (zh) * 2019-07-25 2021-02-02 上海交通大学 抗人egfr嵌合抗体及其制备方法和用途
CN116731189A (zh) * 2020-04-24 2023-09-12 美勒斯公司 使用结合lgr5及egfr的抗体的癌症治疗
CN115960214A (zh) * 2021-10-12 2023-04-14 中国科学院分子细胞科学卓越创新中心 中和呼吸道合胞病毒的全人抗体的设计及应用
EP4476263A4 (en) * 2022-02-09 2026-01-28 Dragonfly Therapeutics Inc PHARMACEUTICAL FORMULATIONS AND THERAPEUTIC USES OF MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO EGFR, NKG2D AND CD16

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
BRPI0607315B1 (pt) * 2005-02-07 2022-05-17 Roche Glycart Ag Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
US20110200595A1 (en) * 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
EP2603528B1 (en) * 2010-08-10 2016-10-12 Glycotope GmbH Fab-glycosylated antibodies
BR112013003257A2 (pt) * 2010-08-10 2016-06-14 Glycotope Gmbh anticorpos egfr humanizados.

Also Published As

Publication number Publication date
CA2908819A1 (en) 2014-10-30
CN105229030A (zh) 2016-01-06
KR20150144804A (ko) 2015-12-28
SG11201507743XA (en) 2015-11-27
BR112015025955A2 (pt) 2017-10-17
ZA201507246B (en) 2016-12-21
EP2989126A1 (en) 2016-03-02
US20160068609A1 (en) 2016-03-10
WO2014173886A1 (en) 2014-10-30
JP2016516800A (ja) 2016-06-09
EA201591977A1 (ru) 2016-06-30
AU2014257650A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
BR112015025955A2 (pt) tratamentos anticancerosos com anticorpos anti-egfr apresentando uma baixa fucosilação
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
MX2015014500A (es) Terapia de combinacion de anticuerpos contra csf-1r y agonista de tlr9.
PT2958945T (pt) Terapia de combinação envolvendo anticorpos contra claudina 18.2 para tratamento de cancro
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
WO2015009726A3 (en) Medical uses of cd38 agonists
MX384751B (es) Tratamiento del cáncer con una combinación de plinabulina y taxano.
PH12016500839A1 (en) Combination theraphy of an anti cd20 antibody with a btk inhibitor
EA201890411A1 (ru) Терапевтически активные соединения и способы их применения
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
HK1221424A1 (zh) 治疗癌症的药物组合
NZ701974A (en) Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation
HK1221174A1 (zh) 用於治疗癌症的包括tor激酶抑制剂和5-取代喹唑啉酮化合物的组合疗法
GEAP202114756A (en) Combination therapy for the treatment of cancer
HK1221144A1 (zh) 用於治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
EP3052122A4 (en) Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
HK1221150A1 (zh) 用二氢吡嗪并-吡嗪类对癌症的治疗
HK1214752A1 (zh) 由产甲烷菌引起或与之相关的疾病及病状的诊断、选择及治疗方法
EP3019138A4 (en) Guiding means for administering acupuncture and other healing procedures
ZA201708686B (en) Nanoparticles for use as a therapeutic vaccine
MX2016007445A (es) Inhibidores de f1f0-atpasa de trifluorometil pirazolil guanidina y usos terapeuticos de los mismos.
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
EA201690445A1 (ru) Лечение рака
EP3071294A4 (en) Skin cancer treatment using low intensity ultrasound
HK1220133A1 (zh) 改善微血管完整性的方法